More than a dozen companies, including Amgen, Biosource Proteomics,
Glaxo Wellcome, Hoffmann-La Roche, Incyte Genomics, Millennium
Pharmaceuticals, and Oxford GlycoSciences, are using proteomics-the
study of protein expression and function-to advance drug or
diagnostic discovery and development. Preliminary results suggest that
this new field will quickly lead to better pharmaceuticals in certain
therapeutic areas, but with hundreds of tools to choose from and
dozens of emerging applications, picking the right approach is
critical. This report facilitates such decision making. It forecasts
how proteomics will most successfully be used, in which therapeutic
areas it will have its first impact, and how its various tools and
approaches will evolve.
Proteomic technologies and applications of more than 50 companies
are discussed, and detailed profiles, with contact information, are
provided for 23 companies.
Written in language targeting business professionals, this report:
--Describes proteomics and how it is being used
--Evaluates current and emerging tools and approaches
--Assesses industry leaders and their strategies
--Examines prospects for various therapeutic and other applications
View Cart
